CSL Behring Launches My Access™ Cost Share Program during Hemophilia Awareness Month
My Access Offers Out-of-Pocket Payment Assistance to Eligible People in the United States Who Are Treating Hemophilia A or von Willebrand Disease with a CSL Behring Therapy
King of Prussia, PA — 25 March 2014
People who are treating hemophilia A or von Willebrand Disease (VWD) with a
therapy may now be eligible for financial support through the company’s
My Access™ cost share program.
My Access helps hemophilia A and VWD patients, who have private insurance, cover the out-of-pocket costs, up to $12,000, associated with treatment.
“CSL Behring has a long history of providing medical innovations and supportive services that make a meaningful difference in the lives of people with a bleeding disorder and those who care for them,” said Lynne Powell, Senior Vice President, North America Commercial Operations, CSL Behring. "My Access serves as another example of CSL Behring’s longstanding commitment to people who are living with a bleeding disorder and we are proud to officially launch this program during Hemophilia Awareness Month.”
My Access is available through CSL Behring’s
MySource™ program. For My Access participants, CSL Behring will coordinate with specialty pharmacies, hemophilia treatment centers and outpatient hospital services to cover, up to $12,000 per year, out-of-pocket expenses associated with their CSL Behring hemophilia A or VWD therapy. Participants can reenroll every year. My Access is open to U.S. residents only. Participants must have U.S.-based private insurance that covers their CSL Behring therapy. Individuals covered by state or federally funded programs, such as Medicare, Medicaid and Veterans Health Insurance, are not eligible.
"My Access represents CSL Behring’s thorough understanding of the challenges facing the bleeding disorders community,” said Jesse Schrader, a patient with hemophilia A, who is enrolled in My Access and is a member of CSL Behring’s
Gettin’ in the GameSM program. “The company’s dedication to addressing the community’s needs is one of the reasons why I choose to partner with CSL Behring.”
For more information, or to enroll in My Access, please visit
www.MySourceCSL.com or call the My Source Hotline at 1-800-676-4266 and speak with a My Source Care Coordinator. My Access is administered by a third party patient services organization.
About My Source™
CSL Behring created My Source to provide members of the bleeding disorders community with a single source of information that will enhance their treatment experience. My Source was also designed to meet the specific needs and preferences of each patient by providing customized information each time he or she visits. My Source offers:
• Education opportunities that provide members of the bleeding disorders community with information about hemophilia and von Willebrand disease (VWD)
• Financial support programs, like My Access, help ensure individuals are able to access their treatment
• Community connections that allow members of the bleeding disorders community to share experiences with one another, both online and in person
About Hemophilia A
Hemophilia is an inherited bleeding disorder characterized by prolonged or spontaneous bleeding, especially into the muscles and joints. In nearly all cases, it affects only males. The disorder is caused by deficient or defective blood coagulation proteins known as factor VIII or IX. The most common form of the disorder is hemophilia A, or classic hemophilia, in which the clotting factor VIII is either deficient or defective. Hemophilia A affects approximately 1 in 5,000 to 10,000 people.
About von Willebrand Disease
Von Willebrand Disease (VWD), the most common hereditary bleeding disorder in the United States, affects approximately 1 to 2 percent of the U.S. population. It is caused by a deficiency or abnormality of von Willebrand factor, a protein in the blood that is necessary for normal blood clotting. Men and women are equally likely to be affected by the disorder. VWD is classified by type of defect, ranging from Type I (the most common and mildest) to Type III (the least common and most severe).
About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.
CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders in certain markets. The company’s products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn. CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of
CSL Limited (ASX:CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit
Senior Manager, Public Relations & Communications